The Centers for Disease Control and Prevention released provisional guidelines for the use of bedaquiline fumarate in children and pregnant women with multidrug-resistant tuberculosis or patients with extrapulmonary multidrug-resistant TB. The agency urged caution in using bedaquiline with CYP3A4-inhibiting drugs. If options are limited, clinicians can consider using the drug for patients with extrapulmonary TB, pediatric and obstetric patients or people with HIV or other comorbid disorders depending on the circumstances, but it is not routinely recommended pending further studies, the agency said.

Related Summaries